Intracellular Biologics

Engaging targets previously considered undruggable

ENTRADA EEV™ TECHNOLOGY

Entrada's Endosomal Escape Vehicle (EEV) technology enables the discovery and development of intracellular biologics

THERAPEUTIC MODALITIES

Entrada's novel intracellular biologics are engineered to allow us to address a wide range of diseases

DELIVERY TO INTRACELLULAR COMPARTMENTS

Entrada's intracellular biologics achieve functional intracellular delivery into multiple disease-relevant intracellular compartments. This unprecedented advance allows our intracellular biologics to engage previously inaccessible targets

~4,000 human proteins located in the cytosol

ADVANTAGES OF ENTRADA'S INTRACELLULAR BIOLOGICS

1

Ability to enter the cell

Thus far, biologics have been used to engage predominantly extracellular targets. Entrada's intracellular biologics enter cells to engage intracellular targets

2

Greater specificity, less off-target toxicity

Compared to small molecules, biologics possess greater specificity for their targets, reducing off-target toxicity

3

Better suited to bind to intracellular proteins

Small molecule-binding pockets are estimated to account for 2-5% of the human proteome. Biologics are better suited to engage intracellular proteins because of their size and specificity

4

Broad biodistribution

Entrada's intracellular biologics have demonstrated broad distribution to multiple disease-relevant tissues